Biogen says goodbye to Vounatsos and remaining Aduhelm hopes
The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?
Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Late-stage pain pipeline refuses to swell
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
It’s official: expect near-zero Aduhelm sales for the foreseeable future
Aduhelm’s status as a commercial nonentity is confirmed, but what does the final coverage decision mean for follow-on amyloid-beta MAbs?
Flotations tank in the first quarter
A correction – as long as it is not too severe – might not be a bad thing for the sector.
Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Significant readouts for small players
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
